| [1] |
Fernández MF, Reina-Pérez I, Astorga JM，et al. Breast cancer and its relationship with the microbiota[J]. Int J Environ Res Public Health，2018，15(8):1747.
|
| [2] |
Peddi PF. Hormone receptor positive breast cancer：state of the art[J]. Curr Opin Obstet Gynecol，2018，30 (1): 51-54.
|
| [3] |
Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer[J]. Expert Rev Anticancer Ther，2018，18(11): 1101-1112.
|
| [4] |
李焱，鲁海玲，霍明鸣，等. 芳香化酶抑制剂耐药机制研究进展[J/CD]. 中华乳腺病杂志(电子版)，2017，11(3):171-174.
|
| [5] |
Borrie AE, Rose RV, Choi YH, et al.Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer[J]. Breast Cancer Res Treat，2018，172(2): 371-379.
|
| [6] |
Luo S, Chen G, Truica C，et al. Role of the UGT2B17 deletion in exemestane pharmacogenetics [J]. Pharmacogenomics J，2018，18(2):295-300.
|
| [7] |
Early Breast Cancer Trialists’Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer：patient-level meta-analysis of the randomised trials[J]. Lancet，2015，386(10 001):1341-1352.
|
| [8] |
霍明鸣，庞慧，李焱，等. 激素受体阳性晚期乳腺癌内分泌治疗的优化选择[J/CD]. 中华乳腺病杂志(电子版) ，2017，11(1): 43-46.
|
| [9] |
Shoombuatong W, Schaduangrat N, Nantasenamat C. Towards understanding aromatase inhibitory activity via QSAR modeling[J]. EXCLI J，2018，17:688-708.
|
| [10] |
Kang H, Xiao X, Huang C, et al. Potent aromatase inhibitors and molecular mechanism of inhibitory action[J]. Eur J Med Chem，2018，143:426-437.
|
| [11] |
Augusto TV, Correia-da-Silva G, Rodrigues CMP, et al. Acquired resistance to aromatase inhibitors: where we stand! [J]. Endocr Relat Cancer，2018，25 (5): R283-R301.
|
| [12] |
Hamadeh IS, Patel JN, Rusin S，et al. Personalizing aromatase inhibitor therapy in patients with breast cancer[J]. Cancer Treat Rev，2018，70:47-55.
|
| [13] |
Elfaki I, Mir R, Almutairi FM, et al. Cytochrome P450: polymorphisms and roles in cancer, diabetes and atherosclerosis[J]. Asian Pac J Cancer Prev，2018，19 (8): 2057-2070.
|
| [14] |
Liu X, Low SK and Boddy AV.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors[J]. Expert Opin Drug Metab Toxicol，2016，12(8): 851-863.
|
| [15] |
Kaewlert W, Sakonsinsiri C, Namwat N，et al. The importance of CYP19A1 in estrogen receptor-positive cholangiocarcinoma[J]. Horm Cancer，2018，9(6): 408-419.
|
| [16] |
Artigalas O, Vanni T, Hutz MH, et al. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis[J]. BMC Med，2015，13:139
|
| [17] |
Shao X, Cai J, Zheng Y，et al. S4646 polymorphism in CYP19A1 gene is associated with the effcacy of hormone therapy in early breast cancer[J]. Int J Clin Exp Pathol 2015，8(5):5309-5317.
|
| [18] |
刘磊，孔凡巍，李庆华，等. CYP19A1基因多态性与晚期乳腺癌阿那曲唑治疗疗效相关性研究[J]. 中国肿瘤，2017，26(9):740-744.
|
| [19] |
Glubb DM, O’Mara TA, Shamsani J, et al. The association of CYP19A1 variation with circulating estradiol and aromatase inhibitor outcome: can CYP19A1 variants be used to predict treatment efficacy? [J]. Front Pharmacol，2017，8:218.
|
| [20] |
Gervasini G, Jara C, Olier C, et al.Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients [J]. Br J Clin Pharmacol，2017，83(3): 562-571.
|
| [21] |
Ferraldeschi R, Arnedos M, Hadfield KD，et al. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients [J]. Breast Cancer Res Treat，2012，133:1191-1198.
|
| [22] |
Johansson H, Gray KP, Pagani O, et al.Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial [J]. Breast Cancer Res，2016，18 (1): 110.
|
| [23] |
Napoli N, Rastelli A, Ma C, et al. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer [J]. Pharmacogenet Genomics，2015，25(8): 377-381.
|
| [24] |
Mazzuca F, Botticelli A, Mazzotti E, et al. CYP19A1 genetic polymorphisms rs4646 and osteoporosis in patients treated with aromatase inhibitor-based adjuvant therapy[J]. Eurasian J Med，2016, 48(1): 10-14.
|
| [25] |
Santa-Maria CA, Blackford A, Nguyen AT，et al. Association of variants in candidate genes with lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy[J]. Clin Cancer Res，2015，22(6):1395-1402.
|
| [26] |
Zheng Y, Xu Y, Zhou BY，et al. CYP3A4*1B polymorphism and cancer risk: a meta-analysis based on 55 case-control studies [J]. Ann Clin Lab Sci，2018，48(4):538-545.
|
| [27] |
Zhang Y, Wu J, Zhou Y，et al. Effects of psoralen on the pharmacokinetics of anastrozole in rats[J]. Pharm Biol，2018，56 (1): 433-439.
|
| [28] |
Hertz DL, Kidwell KM, Seewald NJ，et al. Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer[J]. Pharmacogenomics J，2017，17(6): 521-527.
|
| [29] |
Hertz DL, Henry NL, Rae JM. Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug effcacy and toxicity in breast cancer patients [J]. Pharmacogenomics，2017，18(5):481-499.
|
| [30] |
Tanner JA and Tyndale RF.Variation in CYP2A6 activity and personalized medicine [J]. J Pers Med，2017，7(4):18.
|
| [31] |
Wassenaar CA, Zhou Q, Tyndale RF. CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms [J]. Pharmacogenomics，2016，17(2):147-162.
|
| [32] |
Yang N, Sun R, Liao X, et al.UDP-glucuronosyltransferases (UGTs) and their related metabolic cross-talk with internal homeostasis: A systematic review of UGT isoforms for precision medicine [J]. Pharmacol Res，2017，121:169-183.
|
| [33] |
Abubakar MB, Wei K, Gan SH. The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients [J]. Pharmacogenet Genomics，2014，24 (12): 575-581.
|
| [34] |
Edavana VK, Dhakal IB, Williams S，et al. Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics [J]. Drug Metab Dispos，2013，41(4):870-877.
|
| [35] |
Gregory BJ, Chen SM, Murphy MA，et al. Impact of the OATP1B1 c．521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers [J]. J Clin Pharm Ther，2017，42 (5): 547-553.
|
| [36] |
Rizner TL, Penning TM. Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism [J]. Steroids，2014, 79: 49-63.
|
| [37] |
Platt A, Xia Z, Liu Y，et al. Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases[J]. Pharmacogenet Genomics，2016，26(8): 370-380.
|
| [38] |
Sjostedt N, Holvikari K, Tammela P，et al. Inhibition of breast cancer resistance protein and multidrug resistance associated protein 2 by natural compounds and their derivatives[J]. Mol Pharm，2017，14(1): 135-146.
|
| [39] |
Edavana VK, Penney RB, Yao-Borengasser A，et al. Effect of MRP2 and MRP3 polymorphisms on anastrozole glucuronidation and MRP2 and MRP3 gene expression in normal liver samples[J]. Int J Cancer Res Mol Mech，2015，1(3): 10.16966/2381-3318.112. |
| [40] |
Hertz DL, Barlow WE, Kidwell KM ，et al. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on swog study s0226[J]. Br J Clin Pharmacol，2016, 81(6):1134-1141.
|
| [41] |
Zhang B, Lauschke VM. Genetic variability and population diversity of the human SLCO (OATP) transporter family [J]. Pharmacol Res，2019，139:550-559.
|
| [42] |
Mosly D, Turnbull A, Sims A，et al. Predictive markers of endocrine response in breast cancer [J]. World J Exp Med，2018，8(1): 1-7.
|
| [43] |
Reinert T, Goncalves R, Bines J. Implications of ESR1 mutations in hormone receptor-positive breast cancer [J]. Curr Treat Options Oncol，2018，19 (5): 24.
|
| [44] |
Angus L, Beije N, Jager A，et al. ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients [J]. Cancer Treat Rev，2017，52:33-40.
|
| [45] |
Ho MF, Ingle JN, Bongartz T，et al. TCL1A single-nucleotide polymorphisms and estrogen-mediated toll-like receptor-MYD88-dependent nuclear factor-κB activation: single-nucleotide polymorphism- and selective estrogen receptor modulator-dependent modification of inflammation and immune response [J]. Mol Pharmacol，2017，92(2): 175-184.
|
| [46] |
Ho MF, Lummertz da Rocha E, Zhang C，et al. TCL1A, a novel transcription factor and a coregulator of nuclear factor κB p65: Single nucleotide polymorphism and estrogen dependence [J]. J Pharmacol Exp Ther，2018，365(3): 700-710.
|
| [47] |
Ho MF, Bongartz T, Liu M，et al. Estrogen, SNP-dependent chemokine expression and selective estrogen receptor modulator regulation[J]. Mol Endocrinol，2016，30(3):382-398.
|
| [48] |
St Laurent G, Wahlestedt C, Kapranov P. The landscape of long noncoding RNA classification [J]. Trends Genet，2015，31(5): 239-251.
|
| [49] |
Ingle JN, Xie F, Ellis MJ，et al. Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy [J]. Cancer Res，2016，76(23):7012-7023.
|
| [50] |
Fu X, He Y, Wang X，et al. MicroRNA-16 promotes ovarian granulosa cell proliferation and suppresses apoptosis through targeting PDCD4 in polycystic ovarian syndrome [J]. Cell Physiol Biochem，2018，48(2): 670-682.
|
| [51] |
Chen Z, Yuan YC, Wang Y，et al. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer [J]. Breast Cancer Res Treat，2015，152(1): 29-39.
|